Multidimensional Analysis of Clinicopathological Features on the Prognosis of Epithelial Ovarian Cancer Patients Who Received Neoadjuvant Chemotherapy

Background/Objectives: Epithelial ovarian cancer (EOC) has one of the highest mortality rates among cancers affecting women. Herein we aimed to describe how to estimate the prognosis for EOC with clinicopathological features. Methods: This study included 86 patients with stage III and IV epithelial ovarian cancer who received neoadjuvant chemotherapy and who had been followed up at least one year. Prognostic factors and their impact on survival were evaluated. FIGO staging of the disease, body mass index (BMI), histological subtype, menopause status, ECOG performance status, genetic testing with variations, residual disease, ascites, serum Ca125 levels, platelets, MPV, neutrophils, lymphocytes, monocytes, lymphocyte/monocyte ratio, CRP, protein, LDH levels, albumin, CRP/albumin ratio, modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), systemic inflammatory response index (SIRI), systemic inflammation index (SII), pan-immune inflammation value (PIV), relapse status, type and number of neoadjuvant chemotherapy were evaluated. Results: The median age of the patients was 60.0 years. Median overall survival (OS) was 55.1±8.7 months and median disease-free survival (DFS) was 36,8±5,0 months. No significant differences in survival were observed based on age, BMI, or menopausal status. However, patients with an ECOG score of 0 had significantly longer OS compared to those with an ECOG score of 1 (p